Sonnet BioTherapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Technology
    • Overview
    • Platform
    • Strategy
    • Progress
    • Publications
  • Pipeline
    • Overview
    • Clinical Trials
  • Partnering
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 04, 2022 8:00am EDT

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sep 26, 2022 8:00am EDT

Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company's Business Advisory Committee

Sep 21, 2022 8:00am EDT

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sep 16, 2022 8:30am EDT

Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split

Aug 15, 2022 4:05pm EDT

Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update

Jul 22, 2022 7:00am EDT

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

Jul 21, 2022 7:30am EDT

Sonnet BioTherapeutics Announces Clinical Trial of SON-1010 in Healthy Volunteers

Jun 09, 2022 7:00am EDT

Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

Jun 02, 2022 9:25am EDT

Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

May 10, 2022 8:15am EDT

Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
    © 2023 Sonnet BioTherapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap